Member Info for Bella6532

I fon't give a fud about what the f

WeAreGroot...agree...it's a process...and each itsy bitsy step will affect the next itsy bitsy step...and each step will determine the path of the next step as data is gathered and assessed. Sometimes the steps will be long and slow and other times they might even suddenly move in a totally different direction. It's the data that's king and the driver of each step and it's pathway.

There are also two sides to this business - unless we hear otherwise in the coming days/weeks - and the DX debt has been a real drag on the SP, however, it has allowed the company to expand into Distribution which going forward could also be key from a learning and contact point of view. Very few early stage listed companies are profitable - hence the listing to raise funds as and when needed, so I'm very surprised so few on here seem to get the process.

Anyway, tomorrow should be interesting but don't expect a deal announcement just great data which could potentially lead to a deal/deals as we move closer to Phase 2 which is where it usally all happens...roll on June and H2...

Just over 10m traded today...

It's not just the data release it's about thexwebsite update too...why now...trials still ongoing and only in very early stages...we are seeing a huge change of emphasis...WHY!!!...WHAT HAS CHANGED???...THE DATA MUST BE PRETTY GOOD AND ENOUGH IS NOW KNOWN TO REALLY TRIGGER THE COMMERCIALISATION BUTTON AND STRONG DISCUSSIONS FOR PIPELINE DEALS...IMHO...DYOR...

4.13m traded so far now...

Looks like some of it is ISA topping up...plenty of £19.99K's...

2.23m traded so far this morning...

This is the Avacta website Affimer section heading...if the website isn't updated further it looks like Avacta is just a cancer targetting company now...

Affimer® technology

Next-generation biotherapeutics to surpass the limitations of cancer therapies.

PL75

DX has always been listed on the footer even Friday and yesterday.

My guess is it will be added in again and may even be in an updated format too. I wonder how the DX expansion into Europe is going.

From Dec 2023...

https://www.fiercebiotech.com/biotech/how-novartis-readout-causing-trouble-eli-lillys-14b-radiotherapy-buy

Check out their position on ADCs...

https://www.fiercepharma.com/pharma/jpm24-cancer-players-jump-head-first-adc-field-novartis-ceo-explains-how-hes-resisted

Now I do think they are one to watch...Munro has made nice comments re Avacta trial on X and she obviously knows CC.

'pre|CISIONTM ADC

The Avacta pre|CISION-ADC platform leverages the FAP-activated tumour-specific release mechanism of the pre|CISIONTM technology with the tumour-targeting capability of an antibody or Affimer®.

The mechanism of action of the pre|CISION-ADC model optimises warhead delivery by targeting the warhead to the TME in two ways: with the antibody or Affimer® target and FAP-release in the TME.

Optimisation of the bystander effect is a key benefit of the mechanism of the pre|CISION-ADC platform. The biologic targets the molecule to the TME through a non-internalising mechanism and membrane-bound FAP releases the warhead in the extracellular space, thus equally targeting both antigen-positive and antigen-negative tumour cells.

The dual-delivery by a pre|CISION-ADC drug leveraging both a tumour antigen to target and FAP to release the warhead will significantly reduce the off-tumour toxicities associated with traditional ADC mechanisms'

SIGNIFICANTLY REDUCE THE OFF-TUMOUR TOXICITIES ASSOCIATED WITH TRADITIONAL ADC MECHANISMS.

As I said earlier..roll up Big Pharma and come and get your ADCs wrapped in our beautiful PreCision wrapper...just sign the dotted line and we'll get working on it right away for you and here's our bank details.

All you big pharmas now just need to wrap your newly acquired ADC drugs in a nice little PreCision wrapper...just contact Avacta and a licencing deal can be yours for a cut of the action. Bingo and all those nasty ADC side effects will be history.

The presentation will include updated data from the Phase 1 trial beyond those included in the abstract. A copy of the abstract will be available on Avacta’s website at: https://avacta.com/about/scientific-resources/.

Copies of the poster will be available on Avacta's website following the conference at: https://avacta.com/about/resources/posters/.

Christina Coughlin will provide a video presentation overview examining the data presented in the poster. This will be available on 10th April at https://avacta.com/investors/documents-presentations/.

Alastair Smith, Avacta Chief Executive Officer, will also be hosting a webinar on Wednesday, April 10 2024 at 5.30pm BST to discuss the data. Registration for the event is via the following link:

https://www.turnerpope.com/register/

From abstract conclusion...

'AVA6000 delivers high concentration of doxorubicin to the TME relative to plasma which results in antitumor activity in tumors with high FAP activity.'

'WHICH RESULTS IN ANTITUMOR ACTIVITY...'

'Internal

pre|CISION™ AVA6000 – FAPα activated doxorubicin

Phase 1

pre|CISION™ AVA3996 – FAPα activated proteasome inhibitor

Pre Clinical

AVA028 / 032 – PD-L1 Affimer® / ImmunoCytokines

Research

AVA021 – PD-L1 Affimer® / LAG-3 Affimer®

Research

TMAC® platform

Research

Undisclosed targets

Research

Partnered

LR19128 PD-L1 XT®

Pre Clinical

Undisclosed targets

Research

AFX-001 Solid Organ Transplant

Pre Clinical

AFX-001 Graft vs Host Disease

Pre Clinical

AFX-002 Multiple Sclerosis

Research

CLOSE

TMAC® platform

TMAC® utilises the proprietary pre|CISION™ substrate to provide for the selective release of a drug moiety by FAPα. These FAP-activated Affimer® drug conjugates are designed to release drug moieties in the extracellular space of the tumour, rather than inside the tumour cell as is the case with traditional antibody-drug conjugates (ADCs). This novel class of drug conjugates is terms “tumour microenvironment activated drug conjugates” or TMACs. In the TMAC® format, Avacta can deliver otherwise acutely toxic immune activating molecules, which circulate in an inert form as the conjugate but which release potent activators of innate immunity when the linker is cleaved by FAPα in the tumour and the Affimer® also provides adaptive immune therapeutic activity.'

Peptide Drug Conjugates – Multiple advantages over traditional ADC

See full details on the new Avacta website...

They certainly are going for it...

Let's see how it looks by Sunday/Monday...I suspect it's a rush job update and they still have to download DX back onto site.

And pre|CISIONTM antibody/Affimer® drug conjugates …”....TMAC ???

But TMAC is not in Glossary List..???

Either sold or updates are a co*k up and they forgot to add the DX pages back in or Avacta is making DX a stand alone subsidiary. RNS Monday.